| BioMimetic Therapeutics, Inc. Q1 2010 Earnings Call Transcript BioMimetic Therapeutics, Inc. (BMTI)Q1 2010 Earnings Call TranscriptMay 10, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Kensey Nash, Because Biomaterials Is a Growth Industry Jim Van Meerten submits: Kensey Nash Corporation (KNSY) designs, develops, manufactures, and processes proprietary biomaterials products for the orthopedics, cardiology,drug/biologics delivery and wound care markets. The company also is involved with cardiovascular medical technology, specifically, arterial revascularization and puncture closure devices. The company intends to leverage its proprietary knowledge and expertise to develop new products and technologies and to explore additional applications for its products. In the last 30 days this stock has appreciated 14.71% with 15 new highs in the last 20 trading sessions. On Barchart 12 of the 13 technical indicators have buys for a 96% technical buy signal. The stocks trades at 24.10 with a 50 day moving average of 22.87.Complete Story » seekingalpha.com |
Earnings Preview: Celgene theflyonthewall.com submits: Celgene (CELG) is expected to report Q2 earnings Thursday, July 29 before the market open, with a conference call scheduled for 9 am ET. GuidanceAnalysts are looking for EPS of 66c on revenue of $820.4M. The consensus range is 64c-70c for EPS, and $781.5M-$841M for revenue, according to First Call. Possible positives for Celgene's Q2 results should come from Revlimid and Vidaza sales. Vidaza was recently approved in Europe. Negative factors that may effect this quarter include slower Revlimid sales and the fallout from health care reform. Complete Story » seekingalpha.com |
Feds Intervene in Pfizer Suit Over Illegal Drug Promotion Pharmalot submits: Four months after two sales reps caused a sensation by charging that Wyeth (WYE) illegally promoted its Rapamune kidney transplant drug for use with other organs and targeted African-Americans, the federal government has filed a motion with a federal court to intervene, or join their whistleblower lawsuit. In a document (pdf) filed Tuesday in US District Court in Philadelphia, the US Attorney for Pennsylvania and 19 states, along with the District of Columbia, wrote that “the United States has established good cause to intervene…” An accompanying memorandum, however, was filed separately under seal. Wyeth, by the way, is now part of Pfizer (PFE).Complete Story » seekingalpha.com |
15 Biotech Stocks With the Lowest Put/Call Ratios Kapitall submits:The following is a list of the top 15 biotech stocks in terms of the Put/Call ratio, which measures the number of open call option positions relative to the number of open put option positions.Of all the biotech stocks, these companies have the lowest Put/Call ratios, i.e. the highest level of bullish sentiment in the options market.Complete Story » seekingalpha.com |